Webinar presentation Thursday, March 7, 2019, 12:00pm CDT.
Meningococcal disease, specifically serotype B (MenB), is an ongoing problem in this country, particularly in light of recent university outbreaks. The disease can develop from initial symptoms to death within 24 hours, and as many
as 20% of survivors have permanent sequelae. Notably, incidence rates are often a misconception due to under- detection and under-reporting. Given how disabling diseases can be that could have been prevented with vaccination, it
is essential that healthcare workers delivering vaccinations enhance their standards of care in practice in order to deliver the highest rates of preventative care. The goal of the activity is to improve comprehension and initiate practice changes so as to improve immunization rates for all patients who are currently scheduled for the MenB vaccination.
At the conclusion of this activity, participants will be able to (or better able to):
- Discuss the current epidemiology of MenB in the United States and the profiles of patients at greatest risk for this vaccine-preventable disease.
- Describe recent MenB immunization recommendations made by the Advisory Committee on Immunization Practices (ACIP) and the rationale behind a category B classification.
- Examine the mechanism of action, contraindications, and adverse effect profiles of current MenB vaccines.
- Given a patient case, recognize best practices in counseling patients and their parents/caregivers on the importance of administering the MenB vaccine.
- Discuss practice considerations for administering the MenB vaccine such as documentation, billing, and screening for additional immunizations.
The target audience includes pediatricians and other clinicians who specialize in adolescent health, college health and immunization who care for patients who are scheduled to receive the Meningococcal B vaccine.